Back to Search Start Over

Real-Life Value of the Odysight® Application in At-Home Screening for Exudative Recurrence of Macular Edema

Authors :
Gauthier Kielwasser
Laurent Kodjikian
Corinne Dot
Carole Burillon
Philippe Denis
Thibaud Mathis
Hôpital de la Croix-Rousse [CHU - HCL]
Hospices Civils de Lyon (HCL)
Hôpital d'Instruction des Armées Desgenettes
Service de Santé des Armées
Hôpital Edouard Herriot [CHU - HCL]
Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon
Unité de Nutrition Humaine (UNH)
Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA)
Matériaux, ingénierie et science [Villeurbanne] (MATEIS)
Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon)
Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)
Institut de la Vision
Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Source :
Journal of Clinical Medicine; Volume 11; Issue 17; Pages: 5010, Journal of clinical medicine, Journal of clinical medicine, 2022, 11 (17), pp.5010. ⟨10.3390/jcm11175010⟩
Publication Year :
2022
Publisher :
Multidisciplinary Digital Publishing Institute, 2022.

Abstract

International audience; Background: The aim of this study was to describe the value of the Odysight (R) application in addition to a classical follow-up regimen in the detection of exudative recurrences in patients with macular edema. Methods: We conducted an observational, multicenter, retrospective study. The Odysight (R) application includes a visual acuity (VA) test that can lead to alerts in case of a drop of >5 VA letters on two successive tests. The efficacy of the alerts in detecting exudative recurrence was studied. Results: A total of 149 eyes of 123 patients were included. The sensitivity of alerts for the detection of recurrence was 30.8% (95% CI [17.6; 44.0]) and its specificity was 83.7% (95% CI [73.2; 94.3]). A better baseline VA was found to be significantly associated with a better retention of the application (OR = 0.05, 95% CI [0.002; 0.62]; p = 0.045). Of the 12/39 alerts that detected a recurrence, eight (20.5% of all alerts) resulted in the scheduling or advancement of an intravitreal injection. Conclusions: In the present study, the sensitivity and positive predictive value of the Odysight (R) application seems low but its use in addition to the usual follow-up of the patient can detect, in certain cases, an early recurrence and thus allow an anticipated readjustment of the treatment.

Details

Language :
English
ISSN :
20770383
Database :
OpenAIRE
Journal :
Journal of Clinical Medicine; Volume 11; Issue 17; Pages: 5010
Accession number :
edsair.doi.dedup.....59709ceac90dbf8acb4cd609fc17875e
Full Text :
https://doi.org/10.3390/jcm11175010